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Abstract
Background and aims: The occurrence rate of adverse events (AEs) related to care
among hospitalized oncology patients in Switzerland remains unknown. The primary
objective of this study was to describe, for the first time, the occurrence rate, type,
severity of harm, and preventability of AEs related to care, reported in health records of
hospitalized hematological and solid-tumor cancer patients in three Swiss hospitals.
Methods: Using an adapted version of the validated Global Trigger Tool (GTT) from
the Institute for Healthcare Improvement, we conducted a retrospective record
review of patients discharged from oncology units over a 6-week period during
2018. Our convenience sample included all records from adult patients (≥18 years of
age), diagnosed with cancer, and hospitalized (>24 hours). Per the GTT method, two
trained nurses independently assessed patient records to identify AEs using triggers,
and physicians from the included units analyzed the consensus of the two nurses.
Together, they assessed the severity and preventability of each AE.
Results: From the sample of 224 reviewed records, we identified 661 triggers and
169 AEs in 94 of them (42%). Pain related to care was the most frequent AE (n = 29),
followed by constipation (n = 17). AEs rates were 75.4 per 100 admissions and 106.6 per
1000 patient days.Most of the identified AEs (78%) caused temporary harm to the patient
and required an intervention. Among AEs during hospitalization (n = 125), 76 (61%) were
considered not preventable, 28 (22%) preventable, and 21 (17%) undetermined.
Conclusion: About half of the hospitalized oncology patients suffered from at least
one AE related to care during their hospitalization. Pain, constipation, and nosocomial
infections were the most frequent AEs. It is, therefore, essential to identify AEs to
guide future clinical practice initiatives to ensure patient safety.
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1 | INTRODUCTION
Hospitalized oncology patients are particularly vulnerable to adverse
events (AEs), mainly due to the complexity of cancer disease and toxic
treatments.1-3 AEs are a major cause of patient harm, resulting in
temporary or permanent disability as well as increased morbidity and
mortality.4,5
Measuring AEs is considered a minimum standard of care
and central to patient safety programs.6 Most existing methods
measuring AEs require considerable time and resources.7,8
So-called “trigger tools” based on record review have shown prom-
ising efficiency.9 Triggers are clues in the health record suggesting
a higher likelihood that a patient experienced harm.5 For example,
receiving a blood transfusion is a trigger that could indicate an AE
such as a hemorrhage, which could be related to the insertion of a
catheter. The Institute for Healthcare Improvement (IHI) Global
Trigger Tool (GTT) is among the most widely used trigger tools for
measuring AEs.10,7 The GTT has been used in a variety of settings
and detects minor AEs with greater sensitivity compared to other
methods such as voluntary reporting systems.11 The GTT demon-
strates promising inter- and intra-rater reliability and good sensitiv-
ity and specificity compared to traditional record review.9,12 The
original version of the GTT has been adapted to capture oncology-
specific AEs.13,14 Mattsson et al used the oncology module devel-
oped by the Velindre Cancer Centre15 to supplement the GTT.14
However, this adapted tool did not identify additional AEs specific
to the oncology setting.14 Lipitz-Snyderman et al13 developed an
oncology-specific trigger tool to describe harm (beyond toxicity) in
outpatient and inpatient cancer care settings. The tool includes a
longer list of triggers, yet does not strictly follow the GTT method
and is more time-consuming.13 Using the combination of these two
approaches, and as requested by the IHI, we adapted the GTT
to our local context and named the adjusted tool Swiss Oncology
Trigger Tool (SOTT). To our knowledge, only one study16 has been
conducted in Switzerland applying an adapted GTT method so far.
This analysis of 240 patient charts identified an AE rate of 95.7 AEs
per 1000 patient-days. However, that study was conducted in the
Department of General Internal Medicine at a university hospital
and not specifically in an oncology setting.
In order to improve quality of care and patient safety in oncology,
an effective and reliable monitoring of AEs is necessary. The primary
objective of this study was to describe the occurrence rate, type,
severity of harm, and preventability of AEs related to care reported in
health records of Swiss hospitalized hematological and solid-tumor
cancer patients. As a secondary objective, the GTT was adapted to
the local context and used in hematological and solid-tumor cancer
patients.
2 | METHODS
This descriptive, retrospective study was part of a larger quality and
safety investigation in four oncology units of three large hospitals in
Switzerland. It was reviewed by the local Ethics Committee and was
deemed beyond the scope of the Federal Act on Research involvingHuman
Beings.17 This study used routinely collected data. Patients provided con-
sent for its use in clinical trials upon their admission to the hospital.
An interprofessional team of experts (four physicians, six nurses,
and one researcher) from all three hospitals were involved in the
development/application of the SOTT and chart review/data analysis.
Based on the GTT method, the team consisted of two primary record
reviewers (nurses) and at least one physician who confirmed the con-
sensus of the two primary reviewers.5 The two primary reviewers had
extensive experience in oncology and surgery, and knowledge about
the electronic health records (EHRs) of the included hospitals. Primary
reviewers remained the same across hospitals; secondary reviewers
were four physicians working in the included oncology units.
2.1 | Swiss oncology trigger tool development
The instrument was developed in three stages: (a) research and initial
design of the adapted tool, (b) getting expert feedback and refining the
tool, and (c) reaching consensus and validation of the final tool (Table S1).
The IHI-GTT includes 53 triggers grouped in two general modules (cares
and medication) and four specific modules (intensive care unit, surgery,
emergency department, and perinatal unit).5 We used an iterative expert
consensus method with the interprofessional expert team to adapt the
two general modules to our local setting and to create an additional
oncology module without a formal rating procedure. The triggers com-
prised in the newly developed SOTT included all aspects related to care
independent of the type of healthcare profession. Trigger definitions,
sources used to guide definitions, and the final SOTT version are pro-
vided in Table S2. We were broad in our definition of triggers to make
sure we captured a large scope of AEs.
2.2 | Training and pilot testing
As recommended by the IHI for the GTT, a training phase was
completed before data collection to improve inter-rater reliability
(IRR).5,12 First, both primary and secondary reviewers indepen-
dently studied the GTT documentation provided by the IHI.5 Next,
five health records were randomly selected from each site, using
the same criteria as for the sample in the study, and were
reviewed by primary and secondary reviewers. This allowed
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researchers to create a record review flowchart (Figure S1) to
guide and standardize the review process.
2.3 | Data collection and screening procedure
The screening process consisted of one primary and one secondary
review. Primary reviewers (nurses) reviewed patient records using the
EHR review flowchart (Figure S1). Per the GTT method, a 20-minute
time limit was set for record review. AEs were identified on admission,
during hospitalization, or as a cause of readmission. Secondary
reviewers (physicians) evaluated and analyzed the consensus of the
primary reviewers to reach a final decision on the frequency, type,
severity of harm, and preventability of each AE identified during
hospitalization (Figure 1). If there were disagreements among the
reviewers, a discussion would take place until a consensus was
reached. Due to insufficient contextual data, neither preventability
nor severity of harm was assessed for AEs identified for admission
or as a cause for readmission.
2.4 | Setting and sample
This study was performed in two university hospitals (1550-1900
hospital beds) and one urban tertiary hospital (570 hospital beds) in
Switzerland. One hematological unit, one unit with solid-tumor cancer
patients, and two mixed units (hematological and solid-tumor) were
included in the study, which are the four largest oncology units in
the French-speaking part of Switzerland. Due to differences in the
average length of stay, the nature of the disease, and the types of
treatment, we divided our sample in two groups: hematological and
solid-tumors cancer patients. The units varied in size, ranging between
9 and 23 beds. These wards covered all types of cancer treatment
(chemotherapy, radiotherapy, immunotherapy, bone marrow trans-
plant, hormonotherapy, and targeted molecular therapy) and severity
levels.
We retrospectively reviewed EHRs of patients discharged
over a 6-week period, between January 22nd and March 4th for
the first hospital, between February 5th and March 18th for the
second hospital, and between May 23rd and June 27th for the
third hospital, in 2018. Our convenience sample included all
records from adult patients who were diagnosed with cancer
and hospitalized (>24 hours) in a participating oncology unit.
All records documenting hospital readmission, as defined by
Diagnosis Related Groups18 (within 18 days following discharge),
were also reviewed. Records of cancer patients in complete remis-
sion, hospitalized for surgery/rehabilitation, or not under the
responsibility of the oncology medical team were excluded from
the analysis. The latter concerned cancer patients receiving treat-
ment in the oncology department but hospitalized in other units
(ie, medicine or surgery; Figure 2).19
2.5 | Patient demographics and administrative
variables
Patient age, sex, length of hospital stay, cancer patient group (solid-
tumor or hematological), and cancer type were collected and coded
from EHRs at participating sites. We manually registered the date and
time of hospitalization and of transfer/discharge.
F IGURE 1 Adverse events identification flowchart
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Patients discharged from
solid-tumor cancer wards and
hematological cancer wards
(n=326)
Patients discharged from
solid-tumor cancer wards and
hematological cancer wards,
with a cancer diagnosis (n=273)
Patients without a
cancer diagnosis (n=53)
Hospitalized patients for
surgery/rehabilitation
treatments (n=0)
Patients in complete
remission (n=0)
Patients with a hematological
cancer (n=85)
Patients discharged and
diagnosed with a solid-tumor 
cancer (n=74)
Not under the 
responsibility of the 
oncology medical team
(n=2)
<18 years old
(n=3)
Length of stay 
<24 hours (n=6)
Patients with a «solid-tumor»
cancer (n=188)
Not under the 
responsibility of the 
oncology medical team
(n=11)
<18 years old
(n=1)
Length of stay 
<24 hours (n=26)
Patients discharged and
diagnosed with a solid-tumor 
cancer (n=150)
F IGURE 2 Patient record sampling flowchart19
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2.6 | Study outcomes
2.6.1 | Adverse events
The IHI considers an AE “an unintended physical injury resulting from
or contributed by medical care, that requires additional monitor-
ing, treatment, or hospitalization, or that results in death”.20 Nota-
bly, the IHI definition excludes diagnostic error and harm related
to the omission of care.5 In our study, an AE was only considered
if a clear cause related to care could be established. Here, we
listed all different types of AE to avoid losing relevant information
due to bundling.
Based on the IHI definition of AE,5 we decided to include pain
related to care, persistent fatigue, and psychological distress as AEs
since they are associated to substantial suffering of cancer
patients.21-24 In our study, pain was considered as AE if it was
determined to have been related to care such as puncture/bone
marrow biopsy, peripheral, central, or urinary catheter placement,
dressing change, mobilization, paracentesis, and chemotherapy.
Persistent fatigue was considered as an AE if a relation to the
treatment (eg, chemotherapy or radiotherapy) could be identified.
Psychological distress was considered as AE when it could be
directly associated to care interventions (invasive or noninvasive,
e.g., breaking bad news to patients), or when patients related their
own distress to a care intervention. We analyzed the AEs by can-
cer group to refine the analysis and to see if they differed
between the two groups.
2.6.2 | Severity of harm
The severity of harm related to the AEs was categorized following the
National Coordinating Council for Medication Error Reporting and
Prevention (NCC MERP) Index.25 We used the categories E, F, G, H,
and I, that focused on harm.
2.6.3 | Preventability
Several authors state that assessing preventability can inform
about quality improvement priorities.7,26,27 Thus, we assessed
preventability in this study (Figure 1). Preventability was defined
as failure to apply known methods to avert an injury or harm, and
took into account the clarified cause of the AE.28 An AE was con-
sidered preventable if it would not have occurred if the patient
had received standards of care appropriate at the time of the
study.28,29 Preventability judgement was performed by the sec-
ondary reviewers based on the discussion with primary reviewers.
An AE was considered as “not preventable” if no additional pre-
ventive measures could have been put into place to avoid harm.
An AE was classified as “undetermined” if available data were not
sufficient to determine preventability, or if it was due to an act of
omission.
2.7 | Statistical analyses
Patient demographics and clinical data, number of rehospitalizations
due to an AE, category of harm, and preventability of AEs were reported
using descriptive statistics. To assess the incidence and type of AEs
between cancer patient groups (ie, solid-tumor and hematological cancers),
comparisons were performed using the Wilcoxon-Mann-Whitney test
(age), and proportions test (AE rates, sex). Lengths of stay were analyzed
with the Wilcoxon-Mann-Whitney test. Absolute and relative frequency
of AEs by cancer patient group were determined. We calculated AEs per
1000 patient-days using length of stay data and AEs per 100 admissions
using total admissions (including AEs present-on-admission, during hospi-
talization, and leading to a readmission). Generalized linear model with
Poisson distribution was conducted to assess how many AEs could be
explained by age, sex, length of stay, or cancer patient group (solid-tumor
vs hematological cancer). We tested the interaction effect between length
of stay and cancer patient group using R version 5.3.2 and the
“plot_model” function from the “sjplot” package.
To monitor the quality of the screening process, IRR for trigger
identification between primary reviewers was determined using
unweighted Cohen's Kappa statistic.30 Due to the large number of
patient records and limited number of primary reviewers (two nurses),
IRR was calculated every 10 records.5
For each trigger, a positive predictive value (PPV) was calculated to
assess the trigger's performance31 by dividing the number of times the
trigger led to an identified AE by the total number of times it was identi-
fied.13 Each trigger that indicated zero or more AEs was counted. Median
PPVs for each module were calculated. Weingart et al32 cite PPVs of 17%
to 45% using physician chart review as the gold standard, in general medi-
cine literature. Data were analyzed with Stata 14. For the Poisson model,
we used the general linear model (glm) function of R (version 3.5.2).
3 | RESULTS
A total of 224 patient records (solid-tumor cancer: n = 150, hemato-
logical cancer: n = 74, representing 1585 patient-days) were included.
Patient characteristics are shown in Table 1. Median length of stay
was 3 (IQR 2-8) days for haemato-oncology patients and 3 (IQR 2-6)
for solid-tumor patients; this difference was not statistically significant
difference (P-value = .62, Wilcoxon-Mann-Whitney).
3.1 | AE rates
Overall, 94/224 (42%) of the analyzed EHRs contained at least one
AE. We identified 169 AEs, including 34 AEs on admission, 125 during
hospitalization, and 10 leading to a readmission (Table 3). Forty-nine
patients (49/224, 22%) suffered from one AE and 45 patients
(45/224, 20%) had two or more AEs. A maximum of seven AEs were
identified in a patient during hospitalization (Table S3). A total of
144 AEs were identified by at least one trigger and 25 were identified
without an attributable trigger, through the discharge notes. The most
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frequent cause for readmission was febrile agranulocytosis (3/5;
Table 3). The overall AE rate was 75.4 per 100 hospital admissions
and 106.6/1000 patient-days.
Most AEs (100/169, 59%) were identified in patients with
solid-tumors, while hematological cancer patients had 69 total
AEs (41%). The AE rate was 93 per 100 admissions for hematolog-
ical cancer and 94 per 1000 patient-days, whereas solid-tumor
patients experienced a rate of 67 per 100 admissions and 117 per
1000 patient-days. The rate of AE per 100 admissions was signifi-
cantly different between the cancer patient groups (difference in
proportions in absolute value, 26.5, 95% CI, 16.1-37, P < .001);
the rate of AE per 1000 patient-days was not (difference in
proportions in absolute value, 23.2, 95% CI, −54.7-8.3, P = .157;
Table 2).
3.2 | AE Harm severity and type
The majority of AEs occurring during hospitalization caused temporary
harm that required an intervention (98/125, 78%; Category E;
Figure 3). This severity of harm was most often observed among
solid-tumor patients (67/79, 85%). Of those AEs that required initial/
prolonged hospitalization (category F), hematological cancer patients
had 14/46 (30%) AEs compared to solid-tumor cancer patients with
TABLE 1 Patient characteristics (N = 224)
Total records (N = 224)
Solid-tumor cancer
patients (n = 150)
Hemato-logical cancer
patients (n = 74) P value
Age, median (years) [IQR] 61 [52–70] 61 [52–70] 61 [52–70] .80
Sex % (n) .17
Female 100 (104) 72.1 27.9
Male 100 (120) 62.5 37.5
Length of stay, total (days) 1585 852 733
Length of stay, median (days) [IQR] 3 [2–7] 3 [2–6] 3 [2–8] .62
Cancer type, n (%)
Gastrointestinal 43 (29) -
Head and neck 23 (15) -
Pulmonary 21 (14) -
Urological 16 (11) -
Sarcoma 13 (9) -
Breast 10 (7) -
Melanoma 9 (6) -
Central nervous system (CNS) 8 (5) -
Gynecological 7 (4) -
Lymphoma - 46 (62)
Leukaemia - 15 (20)
Myeloma - 13 (18)
TABLE 2 Incidence rate for AEs of a corrected z-test
AEs per 100 admissions AEs per 1000 patient days
Number of patient
records
Number
of AEs
Length of stay,
total (days) Rate %
Difference in
proportions in
absolute value
(CI 95%) P value Rate‰
Difference in
proportions in
absolute value
(CI 95%) P value
Solid-tumor cancer 150 100 852 67
26.5 (16.1-37) <.001
117
23.2 (−54.7 to 8.3)
.157
Hematological cancer 74 69 733 93 94
Abbreviation: AEs, adverse events.
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11/79 (14%). Pain related to care was the most frequent AE in the cat-
egory E for solid-tumor cancer patients (19/67, 28%) and for hemato-
logical cancer patients (6/31, 19%), followed by constipation (13/67,
19% and 3/31, 10%, respectively). The three most prevalent AEs in
category F for solid-tumor and hematological cancer patients were:
nosocomial infection (2/11.18% and 2/14.14%, respectively), respira-
tory distress (2/11, 18% and 1/14, 7%), reaction to a drug (2/11, 18%
and 2/14, 14%).
One solid-tumor cancer patient required an intervention to sus-
tain life (category H) following drug-related kidney failure (acute; 1/1,
100%), and one hematological cancer patient required an intervention
to sustain life following surgery (1/1, 100%).
Types of AEs per cancer patient group are presented in Table 3.
3.3 | AE preventability
In a secondary review, primary and secondary reviewers considered
76/125 (61%) AEs during hospitalization were not preventable and
28/125 (22%) preventable (Table S4). The remaining 21 AEs were
classified as “undetermined.” The most common preventable AEs
included constipation (9/28, 32%), pain related to care (5/28, 19%), and
pressure ulcer (3/28, 11%).
3.4 | AE triggers
Approximately, one-fifth of triggers (140/661, 21%) identified at
least one AE. Trigger PPVs ranged from 0% to 86% (median 26%;
Table 4). Median PPVs of the new oncology module and adapted GTT
modules (cares, medication) were 23%, 46%, and 21%, respectively. IRR
between primary reviewers was high (Cohen's kappa = 0.9).
3.5 | Factors associated with AEs
The Poisson model showed that the number of AEs exhibited a statis-
tically significant increase for both cancer patient groups by length of
stay (Table S5). However, an interaction effect indicated a steeper
slope for patients with solid-tumor cancer. Notably, the number of
AEs increased exponentially for solid-tumor cancer patients compared
to hematological cancer patients (Figure 4).
4 | DISCUSSION
The results of this study using a newly developed tool revealed that
42% of hospitalized Swiss oncology patients experienced at least one
AE. The majority of AEs that occurred during hospitalization caused
temporary harm that required intervention. Pain related to care and con-
stipation were the most common AEs identified. Most AEs were
deemed not preventable. The majority of AEs were identified by a trig-
ger. Comparing the two groups, 59% of AEs were identified in patients
with solid-tumors while 41% were in hematological cancer patients.
4.1 | Triggers
In this study, the PPVs ranged from 0% to 86%. Higher results
were reported by one US13 and one Swiss16 study. PPVs vary
F IGURE 3 Harm severity of identified adverse events (AEs; n = 125). Harm severity scoring denotes an AE that may have contributed to or
resulted in harm to the patient. Category E represents temporary harm that required an intervention; category F was temporary harm that
required initial/prolonged hospitalization and category H an intervention to sustain life was required
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depending on the context and patient populations.31 For a PPV
of 100%, the trigger itself can be the AE, leaving little room for
other AEs to be associated with that trigger. The calculation of
the PPV does not provide any measure on how many events the
trigger identifies but reflects the rate of positive triggers that
raise one or more AEs.31 Therefore, a low PPV may be due to
poor trigger performance and/or low event rates.31 Further
research is needed to define the best performing triggers in a
given context with a given type of population in order to widen
the scope for identifying AEs.
4.2 | Adverse events
One Swiss study using the GTT analyzed 240 patients' charts over
1 year and found that about two thirds of patients suffered from AEs
TABLE 3 AE types by occurrence
AE types (n = 169) Total n
AEs during hospital stay n (%) AEs present on admission n (%) AEs leading to a readmission n (%)
Ha Sb Ha Sb Ha Sb
Pain related to care 29 6 (21) 19 (66) 3 (10) 1 (3) - -
Constipation 17 3 (18) 13 (76) - 1 (6) - -
Anemia 9 1 (11) 2 (22) 2 (22) 4 (44) - -
Nosocomial infection 8 4 (50) 3 (38) 1 (13) - - -
Anaphylactic reaction to a drug 6 3 (50) 3 (50) - - - -
Pressure ulcer 6 0 (0) 3 (50) 2 (33) 1 (17) - -
Psychological distress 5 1 (20) 3 (60) 1 (20) - - -
Hypotension 5 2 (40) 3 (60) - - - -
Drug-related mucositis 5 2 (40) 1 (20) 2 (40) - - -
Febrile agranulocytosis 5 1 (20) 1 (20) - - 1 (20) 2 (40)
Fall with injury 4 1 (25) 3 (75) - - - -
Dehydration 4 2 (50) 1 (25) - 1 (25) - -
Adverse drug reaction 4 1 (25) 2 (50) - 1 (25) - -
Vomiting 4 2 (50) 2 (50) - - - -
Respiratory distress 3 1 (33) 2 (67) - - - -
Thrombocytopenia 3 - 1 (33) 1 (33) 1 (33) - -
Port-a-Cath thrombosis (partial) 3 1 (33) 1 (33) 1 (33) - - -
Anorexia 2 1 (50) - 1 (50) - - -
Confused state (acute) 2 - 2 (100) - - - -
Infiltration/extravasation (i.v.) 2 1 (50) 1 (50) - - - -
Drug-related kidney failure (acute) 2 2 (100) - - - - -
Drug-related neutropenia 2 - 2 (100) - - - -
Deep vein thrombosis 2 - 2 (100) - - - -
Diabetic ketoacidosis 1 1 (100) - - - - -
Acute kidney failure 1 - - - - 1 (100) -
Anorexia 1 - - - - - 1 (100)
Dehydration 1 - - - - - 1 (100)
Insufficient pain management 1 - - - - - 1 (100)
Pleural effusion 1 - - - - - 1 (100)
Pneumonia 1 - - - - 1 (100) -
Postembolization syndrome
with electrolyte imbalance
1 - - - - - 1 (100)
Otherc 30 11 (37) 9 (30) 6 (20) 4 (13) - -
Total 169 46 (27) 79 (47) 20 (12) 14 (8) 3 (2) 7 (4)
aHematological cancer patient group.
bSolid-tumor cancer patient group.
cPlease consult Table S6.
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with harm, during hospitalization.16 This rate of AEs of hospitalized
patients in an internal medicine unit is higher than in our study. Other
studies have found lower rates of AEs in comparison to our findings.
For instance, a Norwegian study using the IHI GTT found that 24.2%
of cancer patients had experienced at least one AE.1 An analysis of
AEs in 400 surgical and 600 medical records of hospitalized patients
in Switzerland showed that 12.3% of these patients had at least one
AE.33 The latter study used the Adverse Patient Occurrence inventory
tool to screen patient records. Nevertheless, the three studies cannot
be directly compared to our study due to differences in study
populations, settings, or methods applied.
We found an overall rate of 106.6 AEs per 1000 patient-days,
including both solid-tumor and hematological cancer patients. In com-
parison, Lipitz-Snyderman et al2 observed 91.2 AEs per 1000 patient-
TABLE 4 Trigger frequencies and positive predictive value (PPV) of triggers
Triggers
Associated with
at least 1 AE n
Total positive
triggers n PPVa (%)
“Cares” module C1 Blood transfusion or use of other blood products 11 31 35
C2 Cardiopulmonary resuscitation, cardiac and/or pulmonary
arrest, or rapid response team activation
- 1 -
C3 Positive blood culture/infections related to care 3 7 43
C4 Decrease in hemoglobin or hematocrit of 25% or greater over
previous value
- 2 -
C5 Fall 4 8 50
C6 Pressure ulcers 5 7 71
C7 Readmission 7 14 50
C8 Physical restraints use 2 4 50
C9 Hyperthermia 9 38 24
C10 Transfer to higher level of care 6 7 86
Module PPVb (median) 46
“Medication” module M1 Diarrhea 3 31 10
M2 Hyperglycemia 4 12 33
M3 Hypoglycemia - 3 -
M4 Serum creatinine 1 4 25
M5 Vitamin K administration 1 6 17
M6 Antihistaminic administration 4 12 33
M7 Naloxone administration - - -
M8 Nausea 6 45 13
M9 Over-sedation/symptomatic hypotension 4 10 40
Module PPVb (median) 21
“Oncology” module O1 Pain 29 108 27
O2 Acute or unusual dyspnea, respiratory physiotherapy, use of
noninvasive ventilation
3 13 23
O3 Extravasation 2 4 50
O4 Port (Port-a-Cath) 5 65 8
O5 Fatigue 2 36 6
O6 Tumor lysis syndrome - 2 -
O7 Anticoagulation 4 100 4
O8 High potassium levels 2 4 50
O9 Constipation 16 46 35
O10 Psychiatrist consultation 2 9 22
O11 Mucositis 4 8 50
O12 Agranulocytosis 1 24 4
Module PPVb (median) 23
Abbreviations: AEs, adverse events; PPV, positive predictive value.
aPPV was calculated by dividing the number of times the trigger led to the identification of an AE by the total number of times the trigger was identified.
bMedian PPV of each module was calculated by determining the median PPV of all triggers within the module.
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days for hospitalized solid-tumor cancer patients, and Classen et al11
revealed 91 events per 1000 patient-days (range: 89-106) including all
adult inpatients of three hospitals during a 1 month period. In contrast,
Haukland et al1 found in their study 37.1 AEs per 1000 patient-days
for both groups of cancer patients. A meta-analysis of AEs measured by
the GTT revealed an average of 61 AEs per 1000 patient days for a
hospitalized patients.31 These findings suggest that the number of AEs
per 1000 patient-days considerably varied between the different stud-
ies, making comparisons difficult. These discrepancies may be due to
several factors: first, the populations/samples of the different GTT
studies, the quality of the documentation, and the training/experience
of reviewers. Second, the restricted time period; in our study, we did
not capture variations like staffing conditions (eg, illness, maternity
leave, personal turnover) and seasonal factors (eg, “common cold” sea-
son) that could have impacted the occurrence of AEs. Although the IHI
recommends an analysis of 20 patient records per month over a full
year,5 we reviewed EHRs of patients discharged over only a 6-week
period, because this study is part of a larger investigation. Third, we
used the SOTT which includes a specific oncology module, which was
not the case in the study from Haukland et al.1 Triggers in the new
oncology module were developed based on the participating institu-
tions' care guidelines, both medical and nursing, thus increasing the like-
lihood of identifying more AEs in this specific setting. Fourth, despite
being considered the “fifth vital sign”,34 pain has not been universally
considered as an AE in prior studies. Pain is described as a physical and
emotional experience associated with actual and potential tissue dam-
age.34 We found that pain related to care interventions was the most
frequent AE. The care interventions that originated pain were suffi-
ciently described in the EHRs to attribute the pain stemming from care.
Furthermore, the National Comprehensive Cancer Network recognizes
psychological distress as interfering with effective coping with cancer
physical symptoms and treatment.23 We believe excluding psychologi-
cal harm as an AE may result in underestimating important sources of
cancer patients suffering. Therefore, we considered it as an AE and
posit that the conceptual definition of AE may require revision. When
psychological distress and pain AEs are excluded from the analysis, rates
decrease from 75,4 to 60/100 admissions and 106,6 to 85/1000
patient-days. Regarding the harm severity of AEs, our findings are
consistent with previous studies, most of them showing temporary
harm (Categories E and F).1,2,26,35
To our knowledge, this is the first study to compare AEs between
patients with solid-tumors and hematological cancers. Per 1000
patient-days, we observed that the number of AEs was higher for
patients with solid-tumors compared to patients with hematological
cancer. This could be due to the higher number of patients with solid-
tumors per 1000 patient days, as their length of stay is shorter than for
patients with hematological cancer. This hypothesis should be verified.
We observed that patients in our cohort with a solid-tumor were more
likely to suffer from AE related to length of stay compared to hemato-
logical cancer patients. Length of stay has already been correlated with
AEs in other studies. Patients with solid-tumors suffered more AEs
related to pain and constipation than hematological cancer patients.
Patients with hematological cancer suffered more AEs related to noso-
comial infections than solid-tumors cancer patients. Several studies1,2,14
have identified infections as the most common AE. The proportion of
AEs classified in category F was higher in patients with hematological
cancer compared to solid-tumor cancer. The highest proportion of
overall AEs in this category was nosocomial infections, with 14% for
hematological cancer and 18% for solid-tumor cancer. This result is in
line with Lipitz-Snyderman et al.2 stating that 16% of AEs are related to
infections for solid-tumor cancer patients.
We determined a lower percentage of preventable AEs (22% vs
32%) compared to prior reports.2 However, the subjective nature of this
type of assessment and the diverse definitions of this concept make
comparisons among studies difficult.13,36 Interestingly, more than half of
the AEs related to pain related to care, dehydration, and falls with injury
were considered by the reviewers as not preventable. A clinician working
in the oncology unit has certainly a deep and valuable insight on the AE's
context, but a risk of bias remains when reflecting on the causes of the
AE, as well as on their preventability. Regardless, the understanding of
preventable AEs can be key to prioritize improvement measures.27
4.3 | Implications
The SOTT based on the methods used by the IHI for the GTT proves to
be a complement to existing approaches in Switzerland.37,38 This study
has shown that the SOTT allows a comprehensive detection of AEs in
oncology units. As recommended, triggers must be adapted to local
practice and settings to achieve a standardized approach.7,31 We are
aware that additional work is needed to apply the SOTT more widely,
such as a uniform definition of AEs and processes to define the level of
harm and preventability. However, SOTT allows the detection of addi-
tional types of AEs compared to commonly used tools and can open
new perspectives in automating trigger events detection.
4.4 | Strengths and Limitations
This study provides first data on the occurrence rate, type, harm
severity, and preventability of AEs related to care for oncology units
F IGURE 4 Number of adverse events (AEs) as a function of the
length of stay predicted by the model in Table S5, line 12, with a 95%
confidence band
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in Switzerland, comparing solid-tumors and hematological cancer
patients. However, we also note several limitations. First, the record
review is subject to documentation bias as AEs were determined
based on information in the EHR. Second, the 6-week data collection
period does not provide insights into how AEs may change over time,
particularly in terms of type and prevalence. Third, preventability or harm
severity of AEs was a subjective assessment by primary and secondary
reviewers and did not follow a standardized and objective assessment.
Secondary reviewers cared for some of the patients included in this
study, which could have biased judgement and agreement between
reviewers on preventability. To minimize bias and inaccuracy in future
studies, we propose to define objective criteria for preventability and to
trace the reviewer's position on each criterion, thereby ensuring repro-
ducibility (typically measured with a chance-adjusted measure such as
the kappa statistic).36 Fourth, demographic data were not collected on
patients' active cancer treatment protocols. Such a level of detail may
provide further insights into treatment-specific AEs. Fifth, this study is
part of a larger investigation on the quality and safety of nursing care in
Swiss oncology units. Therefore, the study time was limited to 6 weeks,
all EHRs that met the inclusion criteria were analyzed during this time
period, and no power estimation was calculated. Sixth, the exclusion of
patients not under the full responsibility of the oncology units might
have resulted in an underestimation of the number of AEs (even though
such selection criteria was in line with the IHI's recommendation). Finally,
the observational nature of the study precludes conclusions on causal
links between the type of AEs and the factors that contributed to these
AEs. The adaptation of the tool to our local context does not make it
generalizable at this stage. Further testing on the sensitivity and specific-
ity of the SOTT is thus required before generalizing the present approach
to other oncology units.
5 | CONCLUSION
The SOTT offers a thorough method and led to the identification of
661 triggers indicating 169 in-hospital AEs in 240 oncology patient
records in three hospitals in Switzerland.
The SOTT is a contribution to GTT's measurements of AE in
oncology patients and may advance the study of cancer patients'
safety and quality of care. Most AEs identified, like pain, constipation,
and nosocomial infections are already well-known in clinical practice.
Measures to prevent and limit their impact are readily available.
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